Caida Lai
赖才达
Caida Lai (赖才达, also known as Chris) is a Taiwan-born, MIT-trained chemical engineering PhD who co-founded and leads METiS Pharmaceuticals (剂泰医药/剂泰科技) as co-founder and CEO . After graduating in 2016, he spent roughly four years at XtalPi (晶泰科技), where he first encountered AI-driven drug development in full , and previously worked as a consultant at McKinsey & Company . He launched METiS in early 2020, just before the pandemic, building an AI-powered drug delivery platform focused on nanoscale formulation tools to enable breakthrough therapies . His early fundraising was challenging—Monolith Capital's Xi Cao invested at a point when, as Lai put it, "there was really nothing" —though FreeS Fund (峰瑞资本) also backed him across multiple early rounds and traced their relationship back more than a decade . His partner at METiS is academician Hongming Chen (陈红敏院士) . The company went public on the Hong Kong Stock Exchange in May 2026, marking Monolith Capital's first HKEX IPO .
AI-generated — may contain errors, please verify.
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
5Y News | Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange listing!
METiS Pharmaceuticals, the world's first publicly listed AI-driven drug delivery company, goes public, ushering in a new era for biopharmaceuticals.
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Heart Capital Congratulates METiS Pharmaceuticals on Successful Listing on the Main Board of the Hong Kong Stock Exchange | Heart Star PORTFOLIO
The world's first publicly listed AI drug delivery company.
Metis Pharmaceuticals lists today, marking Monolith's first HKEX IPO
The scientist who pitched in a KFC just went public today.
Code Moment | Congratulations to METiS Pharmaceuticals on Its HKEX Listing, the World's First AI Drug Delivery Stock
Source Code Capital participated in METiS Pharmaceuticals' angel round in 2020 and continued to increase its stake in subsequent rounds.
The SpaceX of Pharma: Caida Lai's Nanorocket
Only those with fire in their eyes can build rockets.
MaHui Spotlight | Multiple MaHui Members Named to Wealth's 40 Under 40 China Business Elite and Other Lists
Young leaders are driving a revolutionary transformation of productivity.
MaKe | MaHui Member METiS Pharmaceuticals Closes $100 Million Series C, Leading the "AI + Drug Delivery" Track
5Y News | 5Y Capital Portfolio Company METiS Pharmaceuticals Closes $100 Million Series C Round
Focused on "AI-powered drug delivery."
Congratulations to XtalPi on its Successful IPO: How FreeS Fund's Research-Driven Approach Learns from Investing
AI + Robotics Creates First 18C Listing — Congratulations to XtalPi
Success is rarely replicable; what matters is finding your own path | 5Y View x Bota Bio x METiS Pharmaceuticals
Cross-disciplinary methodology for entrepreneurship.
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
Finding True Non-Consensus: Time as a Moat | 5Y Capital Partner Meeting Recap
Focus only on things that are absolutely meaningful.
The unthinkable is precisely what can be thought. | 5Y News Monthly
The big news from last month.
MaHui Entrepreneurs | AI4S Industrialization Roundtable: With So Many Application Scenarios, "AI Tools" Will Deliver Greater Value
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
MaHui | Nearly 40 MaHui Members Named to 36Kr's X·36Under36 S-Class Young Entrepreneurs List
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
Code Engraved | METiS Pharmaceuticals Announces Two Consecutive Rounds totaling $150 Million
The most advanced pipeline programs are expected to begin pivotal clinical trials in 2023.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
Source Code Capital portfolio company METiS Pharmaceuticals announced the completion of angel+ and Pre-A funding rounds totaling over 100 million yuan, with existing investor Source Code Capital continuing to increase its stake.
It was the first to propose building an AI-driven formulation development platform, jointly advancing new formulation drugs to clinical trials.
Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
Why Is AI Drug Discovery So Hot? And How Long Will It Stay Hot? | FreeS Fund Events & Research Recs
Three Slightly Brain-Burning Little Gifts
AI-powered pharmaceutical formulation development company "METiS" announced the completion of a multi-million dollar angel round — Source Code Capital participated as a follow-on investor.
The world's first startup to use AI to drive pharmaceutical formulation development, dedicated to providing drug companies with rapid, precise intelligent formulation R&D through high-throughput formulation platforms and AI computing technologies.
